Anamorelin as a Therapeutic Option for Cancer Cachexia in Advanced Pancreatic Cancer: A Case Report Demonstrating Significant Weight Gain and Quality of Life Improvement

Abstract

Cancer cachexia, which is characterized by weight loss and muscle weakness, is common in patients with pancreatic cancer. Anamorelin, a ghrelin receptor agonist, has shown potential for the management of cachexia in various cancers. We herein report a 64-year-old man with unresectable pancreatic cancer who experienced significant weight gain with anamorelin, allowing for continued chemotherapy and an improved quality of life. Despite disease progression, his response suggests the potential utility of anamorelin as a supportive therapy. Cachexia's complex metabolic changes make treatment difficult; however, anamorelin's appetite and weight gain effects highlight its possible role in managing cachexia in pancreatic cancer. Therefore, further research is required in this regard.